Prescription-grade CBD may help control hard-to-treat seizures caused by a rare genetic disorder, a preliminary study suggests. The study involved 224 patients with tuberous sclerosis complex (TSC) — a genetic condition that affects about one in 6,000 people, according to the U.S. National Institutes of Health. It causes noncancerous tumors to arise throughout the body, and — in 90% of patients — seizures that are often resistant to standard drugs. Researchers wanted to know whether these patients might respond to Epidiolex, a liquid medication that contains purified CBD (cannabidiol). Last year, the U.S. Food and Drug Administration approved Epidiolex for two other rare seizure disorders: Dravet syndrome and Lennox-Gastaut syndrome. That made it the first approved medication to contain an ingredient derived from cannabis plants. CBD is one of hundreds of chemicals found in cannabis, better known as marijuana. CBD differs from THC, the source of the famous marijuana “high.” CBD is present in marijuana but is more abundant in hemp — cannabis plants that have little THC. Despite the Epidiolex approval, researchers still aren’t sure why prescription-grade CBD can help control severe seizures. But standard antiseizure drugs all work by similar mechanisms — and CBD apparently tackles them in a different way, according to Dr. Elizabeth Thiele, who led the new study. “CBD works by a novel mechanism, but we don’t know exactly what… read on >







